International Journal of Humanities Social Science and Management (IJHSSM)
Volume 3, Issue 2, Mar.-Apr. 2023, pp: 509-516 www.ijhssm.org

Primary Guidelines and Prevention of Cardiovascular System

Mrs. RAJASHRI GOPAL JADHAV - *STUDENT [B. Pharma Final Year]*
Dr. NITIN B. KOHALE – *GUIDE & PRINCIPAL [Department of Pharmaceutics]*
Mr. SURAJ B. RATHOD – *ASST. PROFESSOR [Department of Pharmaceutics]*

INSTITUTE -
Vardhman Foundation Nagpur
Vardhman College of Pharmacy Koli Karanja (Lad) Dist. Washim Maharashtra India
Affiliated To Dr Babasaheb Ambedkar Technological University Lonere

Date of Submission: 11-03-2023 Date of Acceptance: 24-03-2023

ABSTRACT-
Heart disease describes a range of conditions that affect the heart. Cardiovascular disease is a significant and ever-growing problem according to the research (WHO), accounting for nearly one-third of all deaths i.e., around 17.9 million deaths (2019) and leading to significant morbidity. It is also of particular and pressing interest as developing countries experience a change in lifestyle which introduces novel risk factors for cardiovascular disease, leading to a boom in cardiovascular disease risk throughout the developing world. The burden of cardiovascular disease can be ameliorated by careful risk reduction and, as such, primary prevention is an important priority for all developers of health policy. Strong consensus exists between international guidelines regarding the necessity ofsmoking cessation, weight optimization and the importance of exercise, whilst guidelines vary slightly in their approach to hypertension and considerably regarding their approach to optimal lipid profile which remains a contentious issue.

Keywords: Cardiovascular disease, primary prevention, exercise, diet, hypertension, smoking, alcohol, uric acid.

I. INTRODUCTION-

Cardiovascular disease (CVD) is a branch term for a number of linked pathologies. Cardiovascular conditions (CVDs) are a group of diseases of the heart and blood vessels which includes, coronary heart disease – a disease of the blood vessels supplying the heart muscle; cerebrovascular disease – a disease of the blood vessels supplying the brain; supplemental arterial disease – a disease of blood vessels of the arms and legs; rheumatic heart disease – damage to the heart muscle and heart faucets from rheumatic fever, caused by streptococcal bacteria; natural heart disease – birth blights that affect the normal development and functioning of the heart

Heart attacks and strokes are generally acute events and are substantially caused by a blockage that prevents blood from flowing to the heart or brain. The most common reason for this is a figure- up of adipose deposits on the inner walls of the blood vessels that supply the heart or brain.

caused by deformations of the heart structure from birth; deep vein thrombosis and pulmonary embolism – blood clots in the leg modes, which can dislodge and move to the heart and lungs. Encyclopedically CVD accounts for 31 % of mortality, the maturity of this in the form of CHD and cerebrovascular accident. The rate of CVD worldwide is prognosticated to increase as the frequency of threat factors for CVD rises in preliminarily low- threat countries. presently 80% of CVD mortality occurs in utmost developing nations by 2021, catching contagious disease. Not only is CVDa leading cause of mortality, but it's the leading cause of loss of disability- acclimated life time's encyclopedically. [1]

Strokes can be caused by bleeding from a blood vessel in the brain or from blood clots. The World Health Organization (WHO) estimate that over 75% of unseasonable CVD is preventable and threat factor amelioration can help reduce the growing CVD burden on both individualities and

International Journal of Humanities Social Science and Management (IJHSSM)
Volume 3, Issue 2, Mar.-Apr. 2023, pp: 509-516 www.ijhssm.org

healthcare providers. Whilst age is a known threat factor for the development of CVD, autopsy substantiation suggests that the process of developing CVD in after times isn't ineluctable, therefore threat reduction is pivotal. The INTERHEART study illustrated the effect of CVD threat factors including dyslipidemia, smoking, hypertension, diabetes, abdominal rotundity, whilst it demonstrated the defensive goods of consumption of fruits and vegetables, and regular physical exertion. These threat factors were harmonious throughout all populations and socioeconomic situations studied, helping to establish the viabilityof invariant approaches to CVD primary prevention worldwide. [2]

II. METHOD -

We looked specifically at the current National Institute for Health and Care Excellence (NICE) guidelines. European Society of Cardiology (ESC) guidelines as well as guidelines from the American Heart Association (AHA) and American College of Cardiologists (ACC) or, in the case of hypertension, guidelines appertained to by the ACC.

Measurements- For the assessment of rotundity, the height and weight were measured by standardized ways, grounded on the recommendations of NHANES (National Health and Nutrition Examination checks) anthropometry and physical exertion examiner procedures homemade. [4] Individualities were counted bare bases using an electronic scale (LAICA ®, particular Scale; Mod. PS50090, recorded to the nearest0.1 Kg. Height was measured without shoes using movable stadiometer (Seca ®, 213) and recorded to the nearest 0.5 cm. Recommendations for blood pressure dimension, systolic and diastolic blood pressures were measured for three readings with a digital blood pressure (Omron ®, M3 IT) machine. [5]

A normal of the alternate and the third reading was taken. Random blood glucose dimension was taken with a digital glucose cadence (Accu- Chek ® Performa) following the procedure explained in the primer. [6]



ESC approved applications for detection of CVD, CVD Calculation Risk App:

Assess individual cardiovascular risk for different patient populations,Includes up to 10-year risk and lifetime risk calculators. Risk prediction tools: The article "Risk prediction tools in cardiovascular disease prevention" provides a summary of the available risk prediction algorithms and offers guidance on how to use them.
The SMART Risk Score: Easy-to-use, online tool to estimate 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease. [8]

III. DISCUSSION-

Some highlighted areas targeted by these guidelines and primary prevention in cardiovascular disease', then a combination of 'diet', 'hypertension', 'lipids', 'exercise', 'smoking', 'alcohol', 'polypill', 'weight', 'blood glucose' and the term 'cardiovascular disease prevention'.

Exercise - Exercise is widely honored as having a positive impact on the maturity of health issues and its effect on CVD is no different. Mortality and morbidity directly due to exercise remains minimum indeed up to veritably violent situations of exercise and in the inviting maturity the benefits overweigh the pitfalls. NICE recommend 150 twinkles of moderate intensity aerobic exertion per week, or 75 minutes of vigorous aerobic exertion. The guidelines all state that any form of exercise provides CVD threat reduction, with those recently starting exercise achieving topmost benefit and any

posterior increases furnishing significant but dwindling returns.

Diet - Diet is allowed to play a significant part in CVD threat but the body of substantiation regarding its use isn't clear, nor are the guidelines They also suggest a high fiber diet and two portions of fish per week. They do admit that they switching from impregnated to polyunsaturated adipose acids, an increase in fiber, fruit, vegetable and fish input as well as abstinence from alcoholand adherence to a Mediterranean type diet. These have all been shown to offer significant reductions in CVD threat but rather that they've benefits on other areas of health.

Smoking -Smoking has long been known as the major threat factor for CVD. Passive smokingis also dangerous as plant exposure increases CVD threat by 30%. Stopping smoking is the single most cost-effective intervention in CVD prevention, and some benefits are seen within months of conclusion. All NICE guidelines recommend conclusion, with short and long- term benefits seen irrespective of length or intensity of smoking habit. E-Cigarettes are still controversial with respects to CVD threat. Whilst the reduction in poisonous products within cigarette bank is really salutary, beast models of nicotine exposure still display CVD goods with increased atherosclerotic pillars set up in mice models.

Weight - Having a body mass indicator (BMI) > 25 is a threat factor for CVD with smallest all- cause mortality seen at BMI 20 – 25 but due to increase each- beget mortality with BMI<28, reductions below this position aren't routinely recommended.

MEDICAL TREATMENT

Lipid-Lowering Therapy - Interventions to ameliorate lipid levels have long been used in primary preventionand sub-fractions of serum lipids have been studied to differentiate their individual effects on CVD risk profile. LDL-C is the best understood atherogenic sub fraction with a strong correlation between LDL-C levels and CVD risk: reducing LDL-C by 1.0 mmol/L causes a corresponding 20–25% risk reduction in CVD mortality and non-fatal MI. It has been hypothesized that raised high-density lipoprotein cholesterol (HDL-C) levels are cardio protective but the causal link remains unproven. This controversy is borne out by the adverse CVD profile of HDL raisingdrugs such as torcetrapib, as well as recent mendelian randomization analysis suggesting no intrinsic benefit from naturally higher levels of HDL-C. Apolipoprotein B (ApoB) seems a similar predictor of CVD risk to LDL, overwhelmingly consensual. NICE recommend reducing impregnated fat input, adding monounsaturated adipose acids and five portions of fruit and vegetables per day.

No guidelines recommend specific intervention regarding weight, but advise conservation of a healthy weight for reduction of CVD threat. BMI is a good predictor of CVD threat, particularly at advanced situations, but there's good substantiation that, at all situations of BMI, visceral obesity and liver fat are significant motorists 29% of threat. This helps to explain the diversity in the CVDthreat profile seen in the fat as it varies depending on the position of adipose deposit.

Alcohol - Alcohol consumption is a controversial subject given the known sequelae of regular and redundant alcohol use. The difficulty exists as historically the substantiation suggested a J-shaped wind when it comes to threat, where abstinence is associated with an increase in CVD compared to light alkies, with low situations of alcohol consumption associated with a lower position of CHD. Besides the understood physiological goods of alcohol, snooping with platelet aggregation, substantiationfrom the INTERHEART study would appear to substantiate these claims, showing reductions in threat for those with moderate and light use of alcohol. NICE guidelines were produced previous to this data being released and continue with advice on moderate input, advising not further than four units per day for men andthree for women, despite these being arbitrary numbers. [7]

whilst serum triglycerides lack the strength of data of LDL but remain an independent risk factor for CVD. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor, commonly referred to as statins, have been used since the 1980s to reduce LDL-C levels. Their side effect and risk profile is well recognized, with a reported 5–10% experiencing significant side-effects, commonly in the form of myalgia, arthralgia and temporary gastrointestinal upset.

Anti-Hypertensive Therapies - Hypertension is an independent risk factor for the development of CVD. The effectof increasing BP>115/75mmHg is consistent and exponential, where each 20mmHg increase in systolic blood pressure (SBP) or a 10mmHg increase in diastolic BP doubles the risk of a cardiovascular event.40 Previous meta-analyses have shown a reduction in CVD risk over a wider range of BPs suggesting that there is no

International Journal of Humanities Social Science and Management (IJHSSM)
Volume 3, Issue 2, Mar.-Apr. 2023, pp: 509-516 www.ijhssm.org

lower limit to the benefit of BP reduction, and no obvious cut-off at which further reductions become harmful.41,42 Contemporary meta-analyses indicate that the benefits of lowering BP from a baseline<140 may be equivocal oreven detrimental. Combining this evidence would suggest that BP reductions in hypertensive reduce mortality, but for normotensive or pre-hypertensive patients there is little evidence for early treatment. Given that associated with CVD risk in non-diabetics. On average diabetes mellitus (DM) riskof CVD, whilst those with impaired fasting glucose (IFG) are known to be at significant risk of CVD as well as progression to DM. In DM serum glucose reduction is shown to reduce CVD, with lowest risk at normal blood sugars. Recent trials from the sodium/glucose transporter 2 inhibitor class of oral hypoglycemic such as empagliflozin have been shown to significantly reduce all-cause mortality by 32%,as well as CVD death by 28% and HF by 35% in comparison with standard care. It appears that these effects were not mediated by reduction in glucose, rather cardio- renal hemodynamic effects, but the substantial benefits demonstrated would recommend its early use in diabetic patients. Current guidelines need to be updated with further data on these medications.

Anti-Platelet Therapy - Anti-platelet therapy is a significant contributor to secondary prevention but should be avoided in primary prevention in those without comorbidities due to increased bleeding risk with no evidence of CVD risk reduction. In patients with DM the advice is conflicting: ESC guidelines maintain that the bleeding risk exceeds hypertension acts as an independent risk factor for CVD, and synergistically with other risk factors, it is the consensus opinion that the threshold for treatment of hypertension in those at risk of CVD should be lower.

Blood Glucose - Glucose control is pertinent in the diabetic populations but is non-significant

the benefits of aspiring therapy, whilst the American College of Chest Physicians recommend aspirin therapy in patients with DM and 10-year CVD event risk of_10%. Further areas of research. Other areas include the polypill, uric acid and homocysteine. The use of a polypill – a combination pill for CVD risk reduction – has impressive theoretical benefits, but meta-analyses on in-vivo data have not demonstrated significant improvement in CVD risk Lowering serum uric acid levels may improve CVD risk, as it is known that both patients with gout or hyperuricaemia receiving urate-lowering therapies have improved CVD and all cause-mortality, however more research is needed to clarify if these benefits translate to population-wide risk reduction. Homocysteine is a known atherogen, but lowering therapies have not demonstrated a reduced CVD.
RISK FACTORS - The most important behavioral risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioral risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity.

Cardiovascular disease risk categories based on SCORE2 and SCORE2-OP in apparently healthy people according to age ESC

	<50 years	50-69 years	≥70 years[a]
Low-to-moderate CVD risk: risk factor treatment generally not recommended	<2.5%	<5%	<7.5%
High CVD risk: risk factor treatment should be considered	2.5 to <7.5%	5 to <10%	7.5 to <15%
Very high CVD risk: risk factor treatment generally recommended[a]	≥7.5%	≥10%	≥15%

Fig.1 CVD's risk categories

These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure. The most important behavioral risk factors leading to heart disease and strokes are: An unhealthy diet. Physical inactivity. Smoking. Alcohol consumption. High blood pressure. Diabetes, High blood cholesterol and fat levels. CVD's Risk and risk factor treatments in CVD patients, CVD's Risk and risk factor treatment in apparently healthy person, CVD's Risk and risk factor treatment in type 2 diabetes patients. Cessation of tobacco use,

reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviors. There are also a number of underlying determinants of CVDs. These are a reflection of the major forces driving social, economic and cultural change globalization, urbanization and population ageing. Other determinants of CVDs include poverty, stress and hereditary factors. In addition, drug treatment of hypertension, diabetes and high blood lipids are necessary to reduce cardiovascular risk and prevent heart attacks and strokes among people with these conditions.

COMMON SYMPTOMS - Symptoms of heart attacks and strokes. Often, there are no symptoms of the underlying disease of the blood vessels. A heart attack or stroke may be the first sign of underlying disease. Symptoms of a heart attack include; Pain or discomfort in the center of the chest; and/or Pain or discomfort in the arms, the left shoulder, elbows, jaw, or back.

In addition, the person may experience difficulty in breathing or shortness of breath; nausea or vomiting; light-headedness or faintness; a cold sweat; and turning pale. Women are more likely than men to have shortness of breath, nausea, vomiting, and back or jaw pain. The most common symptom of a stroke is suddenweakness of the face, arm, or leg, most often on one side of the body.

Other symptoms include sudden onset of:
Numbness of the face, arm, or leg, especially on one side of the body, confusion, difficulty speaking or understanding speech, difficulty seeing with one or both eyes, difficulty walking, dizziness and/or loss of balance or coordination, Severe headache with no known cause, fainting or unconsciousness.

Symptoms of a Heart Attack Include - Pain or discomfort in the center of the chest, pain or discomfort in the arms, the left shoulder, elbows, jaw, or back, nausea, light-headedness or fainting, sweating, women are more likely to experiencing of breath, nausea, vomiting, and back orjaw pain.

Symptoms of a Stroke Include - Sudden weakness of the face, arm, or leg, most often on one side of the body. Numbness of the face, arm, or leg, especially on one side of the body. Difficulty in speaking or understanding speech. Difficulty in seeing with one or both eyes. Difficulty in walking, dizziness, loss of balance, or coordination. Severe headache with no known cause. Fainting or loss of consciousness.



Fig.2 CVD's Differ

International Journal of Humanities Social Science and Management (IJHSSM)
Volume 3, Issue 2, Mar.-Apr. 2023, pp: 509-516 www.ijhssm.org

WHO staff prepared an initial list of interventions for each condition based on the ICHI codes and proposed a list of medical devices for each of them, **WHO GLOBAL NCD ACTION PLAN -** NCDs – including cardiovascular diseases, cancers, chronic respiratory diseases and diabetes are the world's biggest killers. More than 40 million people die annually from NCDs (74% of global deaths), including more than 15 million people who die too young between the ages of 30 and 70. Low- and middle-income countries already bear 85% of the burden of these premature deaths. Most of these premature deaths from NCDs are largely preventable by enabling health systems to respond more effectively and equitably to the health care needs of people with NCDs and influencing public to be reviewed by experts. This first draft was presented in a workshop and session at the fourth WHO Global Forum on Medical Devices in India.
policies in sectors outside health that tackle shared risk factors, including tobacco use, unhealthy diet, physical inactivity and the harmful use of alcohol. To strengthen national efforts to address the burden of NCDs, the World Health Assembly endorsed the WHO Global Action Plan for the Prevention and Control of non-communicable Diseases 2013–2020 in May 2013. The Global NCD Action Plan provides Member States, international partners and WHO with a roadmap and menu of policy options that, when implemented collectively between 2013 and 2020, would contribute to progress on nine global NCD targets to be attained in 2025. [9]



Fig.3 - Voluntary global targets for prevention and controlof NCDs to be attained by 2025

One of these nine targets specifically address the issue of access to medical technologies and aims at an increase up to "an 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major non-communicable diseases in both public and private facilities".

Why are cardiovascular diseases a development issue in low- and middle- income countries?

At least three-quarters of the world's deaths from CVDs occur in low- and middle-income countries. People living in low- and middle-income countries often do not have the benefit of primary health care programme for early detection and treatment of people with risk factors for CVDs. People in low- and middle-income countries who suffer from CVDs and other non-communicable diseases have less access to effective and equitable health care services which respond to their needs. As a result, for many people in these countries detection is often late in the course of thedisease and people die at a younger age from CVDs and other non-communicable diseases, often in their most productive years. The poorest people in low- and middle-income countries are most affected. At the household level, evidence is emerging that CVDs and other non-communicable diseases contribute to poverty due to catastrophic health spending and high out-of-pocket expenditure. At the macro-economic level, CVDs place a heavy burden on the economies of low- and middle-income countries.

How can the burden of cardiovascular diseases be reduced?

COMMITMENT OF SUSTAINABILITY -

Reduce carbon emissions.Minimize waste.
Reduce water use.
Make sustainable choices about procurement.
Support biodiversity and nature recovery.

The key to cardiovascular disease reduction lies in the inclusion of cardiovascular disease management interventions in universal health coverage packages, although in a high number of countries health systems require significant investment and reorientation to effectively manage CVDs. Evidence from 18 countries has shown that hypertension programme can be implemented efficiently and cost-effectively at the primary care level which will ultimately result in reduced coronary heart disease and stroke. Patients with cardiovascular disease should have access to appropriate technology and medication. Basic medicines that should be available include: Aspirin, Beta-blockers, Angiotensin-converting enzyme inhibitors, And statins. An acute event such as a heart attack or stroke should be promptly managed.Sometimes, surgical operations are required to treat CVDs. They include: Coronary artery bypass, Balloon angioplasty (where a small balloon-like device is threaded through an artery to open the blockage), Valve repair and replacement, Heart transplantation, and artificial heart operations. Medical devices are required to treat some CVDs. Such devices include pacemakers, prosthetic valves, and patches for closing holes in the heart.

Adapt to climate change.
Reduce the environmental impacts of digital working.

IV. CONCLUSION -

The objective of CVD prevention is to reduce the occurrence of major cardiovascular events thereby reducing premature disability and morbidity whilst prolonging survival and quality of life. A number of cardiovascular disease operation strategies in the literature reported promising results. Numerous of the multidisciplinary CHF complaint operation programs were more complex than were programs for hypertension and hyperlipidemia-CAD. The mention guidelines demonstrate numerous methods to reduce CVD risk profile with strong consensus regarding smoking and exercise, whilst the fine details may vary slightly for other factors. Pharmaceutical options have developed over the years whilst lifestyle advice remains largely unchanged. A lack of agreement on applicable profitable and clinical issues for assessing the effectiveness of cardiovascular complaint operation strategies is readily apparent. Primary prevention continues to evolve and with greater availability of long-term data comes improved understanding of the means by which we can reduce CVD risk. It is an endeavour that must be continued if we are to reduce the burden of a preventable disease.

REFERENCES -

[1]. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Cardiovascular diseases CVDs.
[2]. Jack Stewart, Gavin Manmathan and Peter Wilkinson, Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. Go To: journals.sagepub.com/home/cvd.
[3]. Iqbal Fahs, Zainab Khalife, Diana Malaeb, Mohammad Iskandarani, and Pascale Salameh, The Prevalence and Awareness of Cardiovascular Diseases, Risk Factors among the Lebanese Population: A

Prospective StudyComparing Urban to RuralPopulations https://doi.org/10.1155/2017/3530902.

[4]. CDC, NHANES Anthropometry and Physical Activity Monitor Procedures Manual, 2005, https://www.cdc.gov/nchs/data/nhanes/nhanes_0506/BM.

[5]. Expert Panel on Detection, Evaluation, and Treatment of High Blood Pressure, "The Seventh Report of the Joint National

[6]. %20high%20blood%20pressure%3A%20the%20JNC%207%20report&author=%20Expert%20Panel%20on%20Detection&author=Evaluation&author=Treatment%20of%20High%20Blood%20Pressure&publication_year=2003.

[7]. Accu-Chek Performa, Accu-Chek®, 2016. https://www.accu-chek.com.au/meter systems/performa.

[8]. NICE guidelines on risk assessment and reduction of CVD https://www.nice.org.uk/guidance/cg181/resources/cardiovascular-disease-risk-assessment-and-reduction-including-lipid-modification-pdf-35109807660997.

[13]. WHO. The top 10 causes of death, 2012. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ index1.html (accessed 10 October 2016).

[14]. The challenge of cardiovascular disease – quick statistics, 2016.Available at: http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/data-and-statistics (accessed 10 October 2016).

[15]. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE Guideline CG181.

[16]. NICE. NICE Guideline CG127. NICE Guidelines, 2011.

[17]. NICE. Cardiovascular disease prevention. NICE Guideline PH25, 2010.

Committee on Prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report," JAMA, vol. 290, no. 2, article 197, 2003. https://scholar.google.com/scholar_lookup?title=The%20Seventh%20Report%20of%20the%20Joint%20National%20Committee%20on%20Prevention%2C%20detection%2C%20evaluation%2C%20and%20treatment%20of

[9]. 2021 ESC Guidelines on cardiovascular disease prevention in clinicalpractice

[10]. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/2021-ESC-Guidelines-on-cardiovascular-disease-prevention-in-clinical-practice.

[11]. WHO list of priority medical devices for management of cardiovascular diseases and diabetes https://www.who.int/health-topics/medical-devices.

[12]. WHO Cardiovascular diseases (CVDs). 2016. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/ (accessed 10 October 2016).